Celularity Inc.

CELU

CIK 0001752828 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$4M
↓-77.4% -$14Mvs FY2024 (Q4)
Gross Profit
$0
↓-100.0% -$11Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    100ROIC 331.5% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.15 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    2Asset Turnover 0.22x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -77.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -244.1% · trend -118.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$579K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$107M
everything owned
Total liabilities
$145M
everything owed
Stockholders' equity
$-38M
shareholder claim
Net debt
$11M
LT debt minus cash

Recent performance · 29 quarters

Revenue↓-77.4% -$14M
$4M
Net Income↓-43.3% -$7M
$-23M
Free Cash Flow↑+32.6% +$1M
$-3M
Operating Margin↓-120.1pts
-244.1%

Drill down